Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236395 | 0.86 | HPGD (0.62) | MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3316460 | 0.84 | LMNA (0.61) | SIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL6687266 | 0.83 | MAPT (0.64) | MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27997682 | 0.82 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL30532598 | 0.82 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL170932 | 0.80 | HPGD (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7988037 | 0.79 | MAPT (0.62) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL30868315 | 0.79 | KMT2A (0.58) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14046551 | 0.79 | HTR6 (0.57) | MAPTALDH1A1MAPK1HTR6 | |
| SCHEMBL9343184 | 0.79 | LMNA (0.63) | SIRT6MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614220-B2 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-24 | — | — | US | disclosed |
| CN-101563351-B | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2013-06-05 | — | — | CN | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20040006101-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003087095-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | SIRT6 2160/4885MAPT 2067/4885ALDH1A1 232/4885 |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | SIRT6 842/4885MAPT 4168/4885ALDH1A1 271/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | SIRT6 2160/4885MAPT 2067/4885ALDH1A1 232/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | SIRT6 2160/4885MAPT 2067/4885ALDH1A1 232/4885 |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | SIRT6 1502/4885MAPT 2462/4885ALDH1A1 3110/4885 |
| US-20040006101-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | SIRT6 2160/4885MAPT 2067/4885ALDH1A1 232/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | SIRT6 2440/4885MAPT 4348/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.